Prognostic indicators in pediatric clinically isolated syndrome

P Iaffaldano; M Simone; G Lucisano; A Ghezzi; G Coniglio; V Brescia Morra; G Salemi; F Patti; A Lugaresi; G Izquierdo; R Bergamaschi; JA Cabrera-Gomez; C Pozzilli; E Millefiorini; R Alroughani; C Boz; E Pucci; GB Zimatore; P Sola; G Lus; D Maimone; C Avolio; E Cocco; SA Sajedi; G Costantino; P Duquette; V Shaygannejad; T Petersen; R Fernández Bolaños; D Paolicelli; C Tortorella; T Spelman; L Margari; MP Amato; G Comi; H Butzkueven; M Trojano; D Spitaleri; MR Rottoli; B Ardito; G Iuliano; E Montanari; E Granieri; G Tedeschi; A Bertolotto; F Granella; G Di Battista; P Gallo; P Cavalla; P Bellantonio; F De Robertis; L Durelli; E Scarpini; M Rezzonico; A Protti; C Solaro; F Corea; A Bosco; M Vianello; MT Ferrò; R Balgera; R Grasso; G De Luca; D Farina; D Travaglini; M di Ioia; V Di Tommaso; L Mancinelli; E Pietrolongo; R Hupperts; ME Rio; M Terzi; M Barnett; M Slee; V Van Pesch; A Savino; J Lechner-Scott; P Grammond; B Singhal; C Zwanikken; M Fiol; L Patrucco; M Paine; P McCombefrom; F Grand'Maison

Journal article

Prognostic indicators in pediatric clinically isolated syndrome

P Iaffaldano, M Simone, G Lucisano, A Ghezzi, G Coniglio, V Brescia Morra, G Salemi, F Patti, A Lugaresi, G Izquierdo, R Bergamaschi, JA Cabrera-Gomez, C Pozzilli, E Millefiorini, R Alroughani, C Boz, E Pucci, GB Zimatore, P Sola, G Lus Show all

Annals of Neurology | Published : 2017

DOI: 10.1002/ana.24938

Download PDF

Abstract

Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06–1.55; 1.42, 1.10–1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60–0...

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Grants

Funding Acknowledgements

The Italian iMedWeb Registry is based on the voluntary participation of each multiple sclerosis center. It has received financial support through annual research grants from the Italian University and Research Ministry (COFIN 2009-2014, M.T.) and through Merck Serono, Novartis Pharma, and Biogen. The MSBase Registry is supported by the MSBase Foundation, a not-for-profit organization that is sponsored by Merck Serono, Biogen Idec, Novartis, Bayer, Genzyme, Sanofi, and Bio-CSL.